TY - JOUR
T1 - Pseudotumor cerebri as a reversible side effect of all-trans retinoic acid treatment in acute promyelocytic leukaemia
AU - Machner, B.
AU - Neppert, B.
AU - Paulsen, M.
AU - Hofmann, C.
AU - Sander, T.
AU - Helmchen, C.
PY - 2008/7/1
Y1 - 2008/7/1
N2 - Headache and bilateral papilloedema in overweight young woman may be indicative of pseudotumor cerebri syndrome (PTC). ‘Idiopathic intracranial hypertension’ (IIH) refers to the PTC, provided that there are no symptomatic causes for elevated intracranial pressure. Such causes may be tumours, meningeal infiltration and cerebral venous sinus thrombosis as well as the use of certain medications including tetracycline, growth hormone or lithium [1]. Other drugs which have been linked to PTC are vitamin A derivatives such as isotretinoin for acne treatment and all‐trans‐retinoic acid (ATRA) which is successfully administered to treat acute promyelocytic leukaemia (APL) [1, 2]. ATRA‐induced PTC has been described by oncologists in several patients with APL, predominantly children and adolescents [3, 4] as well as some adults [5]. In contrast to previous reports, in which treatment was discontinued once PTC had been diagnosed, we describe the clinical course with continuous medication using neurological and ophthalmological monitoring in a patient with APL who developed PTC during treatment with ATRA. Finally, we will discuss a pathophysiological link between vitamin A and PTC.
AB - Headache and bilateral papilloedema in overweight young woman may be indicative of pseudotumor cerebri syndrome (PTC). ‘Idiopathic intracranial hypertension’ (IIH) refers to the PTC, provided that there are no symptomatic causes for elevated intracranial pressure. Such causes may be tumours, meningeal infiltration and cerebral venous sinus thrombosis as well as the use of certain medications including tetracycline, growth hormone or lithium [1]. Other drugs which have been linked to PTC are vitamin A derivatives such as isotretinoin for acne treatment and all‐trans‐retinoic acid (ATRA) which is successfully administered to treat acute promyelocytic leukaemia (APL) [1, 2]. ATRA‐induced PTC has been described by oncologists in several patients with APL, predominantly children and adolescents [3, 4] as well as some adults [5]. In contrast to previous reports, in which treatment was discontinued once PTC had been diagnosed, we describe the clinical course with continuous medication using neurological and ophthalmological monitoring in a patient with APL who developed PTC during treatment with ATRA. Finally, we will discuss a pathophysiological link between vitamin A and PTC.
UR - http://www.scopus.com/inward/record.url?scp=44949184390&partnerID=8YFLogxK
U2 - 10.1111/j.1468-1331.2008.02152.x
DO - 10.1111/j.1468-1331.2008.02152.x
M3 - Letters
C2 - 18452541
AN - SCOPUS:44949184390
SN - 1351-5101
VL - 15
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 7
ER -
